Politics By Nicholas Florko The FDA says it’s in the dark about thousands of dietary supplement ingredients
D.C. Diagnosis By Nicholas Florko As Congress takes up FDA oversight of dietary supplements, a lobbying showdown looms
Exclusive By Nicholas Florko Senate FDA legislation will include dietary supplement, cosmetic reforms
First Opinion By Bernard Zipprich Will the shadow of Aduhelm cloud FDA’s decision-making on an ALS therapy?
First Opinion By Kristin E. Rojas The FDA needs to take another look at laser-based ‘vaginal rejuvenation’
Health By Nicholas Florko and Andrew Joseph It’s too early to tell whether CBD helps against Covid-19 — but researchers worry that won’t stop CBD makers
First Opinion By Elliott J. Millenson Containing Covid-19 requires rapid tests that are highly sensitive to infections. Why is the FDA asking for something different?
Politics By Nicholas Florko Despite fanfare, the FDA’s step toward lowering nicotine levels in cigarettes is a very early one
Politics By Lev Facher Key Senate committee proposes a council to ensure FDA better coordinates on accelerated approvals
Politics By Nicholas Florko Congress moves toward reforming FDA accelerated approvals, but with pharma-friendly concessions
D.C. Diagnosis By Nicholas Florko The FDA’s Rob Califf on importing drugs from Canada, on Aduhelm, and on opioids
Politics By Nicholas Florko Medicare’s Brooks-LaSure expects restrictions on accelerated approval drugs, like those for Aduhelm, to be ‘very rare’
Pharma By Ed Silverman The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant
D.C. Diagnosis By Nicholas Florko The FDA’s ban on menthol in cigarettes clears a major regulatory hurdle
Politics By Nicholas Florko Right to try 2.0: Advocates want to reduce oversight of ‘n of 1’ therapies
Politics By Nicholas Florko CDC, FDA, and NIH staffers aren’t reporting political interference, new watchdog report shows
D.C. Diagnosis By Nicholas Florko Faced with high drug prices, seniors are abandoning cancer drugs at the pharmacy
Politics By Nicholas Florko Califf admits controversy over FDA’s Alzheimer’s drug decision impacted experts’ trust in the agency
Politics By Nicholas Florko Lawmakers face off about the future of the FDA’s accelerated approval pathway
Politics By Nicholas Florko Congress moves toward giving FDA authority over synthetic nicotine products like Puff Bar
Politics By Nicholas Florko FDA asks Congress for more power to regulate certain diagnostic tests, including prenatal screenings
D.C. Diagnosis By Nicholas Florko Is the Senate gearing up to actually pass drug pricing legislation?
Politics By Nicholas Florko 6 approval decisions that will make or break Califf’s first year at the FDA